{"id":"lag3","name":"LAG-3","symbol":"LAG3","route":"/targets/lag3/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6476","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000089692","uniprot":"https://www.uniprot.org/uniprotkb/P18627/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P18627","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4630881","open-targets":"https://platform.opentargets.org/target/ENSG00000089692","civic":"https://civicdb.org/genes/3902/summary","oncokb":"https://www.oncokb.org/gene/LAG3","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LAG3","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=LAG3","depmap":"https://depmap.org/portal/gene/LAG3?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000089692-LAG3","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/3902","omim":"https://www.omim.org/entry/153337"}],"products":[{"id":"favezelimab","name":"Favezelimab","status":"phase-3","modality":"Anti-LAG-3 monoclonal antibody, intravenous, also coformulated with pembrolizumab (MK-4280A)","route":"/drugs/favezelimab/"},{"id":"fianlimab","name":"Fianlimab","status":"phase-3","modality":"Monoclonal antibody (anti-LAG-3)","route":"/drugs/fianlimab/"},{"id":"hlx26","name":"HLX26","status":"phase-2","modality":"monoclonal antibody","route":"/drugs/hlx26/"},{"id":"relatlimab-nivolumab","name":"Relatlimab + nivolumab","status":"approved","modality":"Fixed-dose bispecific combination (anti-LAG-3 + anti-PD-1)","route":"/drugs/relatlimab-nivolumab/"}],"trials":[{"id":"nct05625399","name":"A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma","nct":"NCT05625399","phase":"3","status":"active"},{"id":"fianlimab-phase3-melanoma","name":"Fianlimab + cemiplimab phase 3 (first-line melanoma)","nct":"NCT05352672","phase":"3","status":"negative"},{"id":"relativity-098","name":"RELATIVITY-098","nct":"NCT05002569","phase":"3","status":"negative"},{"id":"nct06246916","name":"A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)","nct":"NCT06246916","phase":"3","status":"recruiting"},{"id":"nct05608291","name":"A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back Af","nct":"NCT05608291","phase":"3","status":"active"},{"id":"nct03486873","name":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb","nct":"NCT03486873","phase":"3","status":"recruiting"},{"id":"nct06264180","name":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","nct":"NCT06264180","phase":"3","status":"recruiting"},{"id":"relativity-047","name":"RELATIVITY-047","nct":"NCT03470922","phase":"2/3","status":"positive"},{"id":"nct05785767","name":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small","nct":"NCT05785767","phase":"2/3","status":"active"},{"id":"nct05800015","name":"A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult ","nct":"NCT05800015","phase":"2/3","status":"active"},{"id":"i-spy-2","name":"I-SPY 2","nct":"NCT01042379","phase":"platform","status":"active"},{"id":"nct06101134","name":"A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed","nct":"NCT06101134","phase":"2","status":"active"},{"id":"nct04895722","name":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) ","nct":"NCT04895722","phase":"2","status":"active"},{"id":"nct05787613","name":"A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients","nct":"NCT05787613","phase":"2","status":"active"},{"id":"nct07058012","name":"A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal","nct":"NCT07058012","phase":"2","status":"recruiting"},{"id":"nct06769698","name":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous ","nct":"NCT06769698","phase":"2","status":"recruiting"},{"id":"nct06190951","name":"A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma","nct":"NCT06190951","phase":"2","status":"active"},{"id":"nct06161441","name":"A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemoth","nct":"NCT06161441","phase":"2","status":"active"},{"id":"nct07281768","name":"Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer","nct":"NCT07281768","phase":"2","status":"recruiting"},{"id":"nct06205836","name":"Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer","nct":"NCT06205836","phase":"2","status":"recruiting"},{"id":"nct06787612","name":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","nct":"NCT06787612","phase":"2","status":"recruiting"},{"id":"nct03916627","name":"Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients","nct":"NCT03916627","phase":"2","status":"active"},{"id":"nct06865339","name":"Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer","nct":"NCT06865339","phase":"2","status":"recruiting"},{"id":"nct05970497","name":"A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors","nct":"NCT05970497","phase":"1/2","status":"recruiting"},{"id":"nct05845814","name":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","nct":"NCT05845814","phase":"1/2","status":"active"},{"id":"nct04938817","name":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","nct":"NCT04938817","phase":"1/2","status":"active"},{"id":"nct04626479","name":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","nct":"NCT04626479","phase":"1/2","status":"active"},{"id":"nct04626518","name":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","nct":"NCT04626518","phase":"1/2","status":"active"}],"pathways":["pd1-checkpoint","t-cell-exhaustion"],"companies":["bms","immutep","merck","regeneron","henlius"],"keyPapers":["paper-checkmate-067-10-year-nejm-2025","paper-relativity-047-nejm-2022","paper-pardoll-immune-checkpoint-blockade-nrc-2012"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[{"class":"pd1-blockade","mechanism":"Alternative checkpoints (LAG-3, TIM-3, TIGIT)","category":"bypass"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}